循环肿瘤细胞检测的临床有效性和实用性分析

doi:10.11904/j.issn.1002-3070.2018.02.016

摘要/Abstract

摘要： 循环肿瘤细胞(Circulating tumor cells,CTC)是一种特殊的可以作为诊断、预测多种肿瘤预后的生物标记物。目前,循环肿瘤细胞并未开始全面的临床应用,但关于循环肿瘤细胞的研究已经展示出较高的临床有效性,尤其是在乳腺癌、肺癌、前列腺癌及结直肠癌领域。本文综述了循环肿瘤细胞在转移癌和非转移癌的研究进展,并分析了循环肿瘤细胞的临床有效性和实用性。

关键词: 循环肿瘤细胞, 临床应用, 临床有效性

Abstract: Circulating tumor cells(CTCs)are a special type of biomarker that can be used as a diagnostic tool to predict the prognosis of multiple tumors.At present,although circulating tumor cells have not been full clinically application,studies on circulating tumor cells have shown high clinical efficacy,especially in the fields of breast cancer,lung cancer,prostate cancer and colorectal cancer.This article reviews the research progress of circulating tumor cells in metastatic cancer and non-metastatic cancer,analyzes the clinical efficacy and practicability of circulating tumor cells.

Key words: Circulating tumor cells, Clinical use, Clinical efficacy

中图分类号:

R730

徐训政, 张好刚, 乔鹏飞, 王夫景. 循环肿瘤细胞检测的临床有效性和实用性分析[J]. 实用肿瘤学杂志, 2018, 32(2): 169-173.

XU Xunzheng, ZHANG Haogang, QIAO Pengfei, WANG Fujing. Clinical efficacy and practicability analysis of circulating tumor cells[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 169-173.

参考文献

1 Ferreira MM,Ramani VC,Jeffrey SS.Circulating tumor cell technologies[J].Molecular Oncology,2016,10(3):374-394.
2 Kirby BJ,Jodari M,Loftus MS,et al.functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device[J].PLoS One,2012,7(4):e35976.
3 Mayer JA,Pham T,Wong KL,et al.FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE^TM platform[J].Cancer Genetics,2011,204(11):589-595.
4 Kanwar N,Hu P,Bedard P,et al.Identification of genomic signatures in circulating tumor cells from breast cancer[J].Int J Cancer,2015,137(2):332-344.
5 Chimonidou M,Kallergi G,Georgoulias V,et al.Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells[J].Mol Cancer Res,2013,11(10):1248-1257.
6 Chimonidou M,Kallergi G,Georgoulias V,et al.Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells[J].Mol Cancer Res,2013,11(10):1248-1257.
7 Mostert B,Sieuwerts AM,Kraan J,et al.Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients[J].Ann Oncol,2015,26(3):510-516.
8 Khoo BL,Warkiani ME,Tan DS,et al.Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells[J].PLoS One,2014,9(10):e99409.
9 Ligthart ST,Bidard FC,Decraene C,et al.Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer[J].Ann Oncol,2013,48(5):1231-1238.
10 Scher HI,Graf RP,Schreiber NA,et al.Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer[J].European Urology,2017,71(6):874-882.
11 Mazel M,Jacot W,Pantel K,et al.Frequent expression of PD‐L1 on circulating breast cancer cells[J].Molecular Oncology,2015,9(9):1773-1782.
12 Paoletti C,Larios JM,Muñiz MC,et al.Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance[J].Molecular Oncology,2016,10(7):1078-1085.
13 Bidard FC,Proudhon C,Pierga JY.Circulating tumor cells in breast cancer[J].Molecular Oncology,2016,10(3):418-430.
14 Loh J,Jovanovic L,Lehman M,et al.Circulating tumor cell detection in high-risk non-metastatic prostate cancer[J].J Cancer Res Clin Oncol,2014,140(12):2157-2162.
15 Thalgott M,Rack B,Horn T,et al.Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy[J].Anticancer Research,2015,35(10):5679-5685.
16 Fiorelli A,Accardo M,Scrima M,et al.Circulating tumor cells in diagnosing lung cancer:clinical and morphologic analysis[J].Ann Thorac Surg,2015,99(6):1899-1905.
17 Ilie M,Hofman V,Long-Mira E,et al.“Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J].PLoS One,2014,9(10):e111597.
18 Bidard F,Peeters DJ,Fehm T,et al.Clinical validity of circulating tumour cells in patients with metastatic breast cancer:a pooled analysis of individual patient data[J].Lancet Oncology,2014,15(4):406-414.
19 Huang X,Gao P,Song Y,et al.Meta-analysis of the prognostic value of circulating tumor cells detected with the Cell Search System in colorectal cancer[J].BMC Cancer,2015,15(1):202.
20 Rahbari NN,Aigner M,Thorlund K,et al.Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer[J].Gastroenterology,2010,138(5):1714-1726.
21 Tol J,Koopman M,Miller MC,et al.Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents[J].Ann Oncol,2010,21(5):1006-1012.
22 Sastre J,Maestro ML,Gómezespaña A,et al.Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab:A Spanish cooperative group for the treatment of digestive tumors study[J].Oncologist,2012,17(7):947-955.
23 Krebs MG,Renehan AG,Backen A,et al.Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer[J].Clinical Colorectal Cancer,2015,14(2):115-122.
24 V Vlaeminckguillem.When prostate cancer circulates in the bloodstream[J].Diagnostics(Basel),2015,5(4):428-474.
25 Scher HI,Heller G,Molina A,et al.Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer[J].J Clin Oncol,2015,33(12):1348-1355.
26 Bidard FC,Michiels S,Mueller V,et al.International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEO adjuvant chemotherapy[J].Cancer Research,2017,77(4 Supplement):31.
27 Pierga JY,Bidard FC,Autret A,et al.Circulating tumour cells and pathological complete response:independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials(BEVERLY-1 and-2)of neoadjuvant chemotherapy combined with bevacizumab[J].Ann Oncol,2016,28(1):103-109.
28 Rack B,Schindlbeck C,Jückstock J,et al.Circulating tumor cells predict survival in early average-to-high risk breast cancer patients[J].J Natl Cancer Inst,2014,106(5):2504-2511.
29 Sotelo MJ,Sastre J,Maestro ML,et al.Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer[J].Ann Oncol,2015,26(3):535-541.
30 Clara BL,Ortega FG,Antonio CLDG,et al.Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection[J].PLoS One,2016,11(2):e0148659.
31 Heidary M,Auer M,Ulz P,et al.The dynamic range of circulating tumor DNA in metastatic breast cancer[J].Breast Cancer Res,2014,16(4):421.
32 Tie J,Wang Y,Tomasetti C,et al.Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer[J].Science Translational Medicine,2017,11(2):117-118.
33 de Bono JS,Scher HI,Montgomery RB,et al.Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer[J].Clin Cancer Res,2008,14(19):6302-6309.
34 Goldkorn A,Ely B,Quinn DI,et al.Circulating tumor cell counts are prognostic of overall survival in SWOG S0421:a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer[J].J Clin Oncol,2014,32(11):1136-1142.
35 Pearl ML,Dong H,Tulley S,et al.Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells(iCTCs)[J].Gynecologic Oncology,2015,137(2):229-238.
36 Ma J,Yao S,Li XS,et al.Neoadjuvant therapy of DOF regimen plus bevacizumab can increase surgical resection ratein locally advanced gastric cancer:A randomized,controlled study[J].Medicine,2015,94(42):e1489.
37 Bidard FC,Pierga JY,Soria JC,et al.Translating metastasis-related biomarkers to the clinic-progress and pitfalls[J].Nat Rev Clin Oncol,2013,10(3):169-179.
38 Bidard FC,Pierga JY.Clinical utility of circulating tumor cells in metastatic breast cancer[J].J Clin Oncol,2015,33(14):1622.
39 Georgoulias V,Bozionelou V,Agelaki S,et al.Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19 mRNA-positive circulating tumor cells:results of a randomized phase II study[J].Ann Oncol,2012,23(7):1744-1750.

[1]	张彦秋,韩阿蒙,李金旺,顾涛,付占昭,毛羽,张子健,杨振. CRT+ARC技术在局部晚期肺癌患者中临床应用的初步研究[J]. 实用肿瘤学杂志, 2019, 33(3): 256-260.
[2]	崔雪阳, 邢承忠. 液体活检在结直肠癌领域的研究及应用现状[J]. 实用肿瘤学杂志, 2018, 32(4): 367-370.
[3]	罗斌,施奇惠,刘嘉湘综述,田建辉审校. 肺癌循环肿瘤细胞的临床意义[J]. 实用肿瘤学杂志, 2016, 30(4): 370-374.
[4]	尹惠子,单明,尤子龙(综述),庞达(审校). 肿瘤发生过程中表观遗传学机制-DNA甲基化的研究进展[J]. 实用肿瘤学杂志, 2015, 29(2): 173-177.
[5]	张百红综述,岳红云审校. 肿瘤的起源:局部或全身？[J]. 实用肿瘤学杂志, 2013, 27(5): 444-446.
[6]	蔡莉, 宋晓薇, 潘丽华, 石光跃, 刘炜, 孙立春, 陈雪松, 赵丽娜. 探讨循环肿瘤细胞的上皮间质转化基因Twist对晚期乳腺癌化疗疗效的影响[J]. 实用肿瘤学杂志, 2013, 27(1): 37-41.
[7]	汤大北, 张清媛, 王静萱, 赵曙, 赵文辉. 雌激素解救晚期内分泌治疗耐药乳腺癌的临床观察[J]. 实用肿瘤学杂志, 2012, 26(4): 289-292.
[8]	钱六七, 刘芊, 刘毅, 张少华, 王涛, 吴世凯, 宋三泰, 刘兵, 江泽飞. 循环肿瘤细胞在转移性乳腺癌中的表达及其与多种血清肿瘤标志物的关系[J]. 实用肿瘤学杂志, 2012, 26(3): 220-224.